Raymond James Maintains Outperform on NeoGenomics, Lowers Price Target to $24
Raymond James analyst Andrew Cooper maintains NeoGenomics (NASDAQ:NEO) with a Outperform and lowers the price target from $53 to $24.
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Recap: NeoGenomics Q4 Earnings
NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
NeoGenomics reported in-line EPS of $-0.14 versus an estimate of $-0.14.
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Dash, Amp Among Top Crypto Movers In 24H
After pulling data from Benzinga Pro the following is the list of top crypto gainers and losers at the time of publication:
Mina Protocol, LooksRare Among Top Crypto Movers In 24H
According to Benzinga Pro, the following are the crypto gainers and losers at the time of publication:
Pocket Network, LooksRare Among Top Crypto Movers In 24H
According to Benzinga Pro, the following are the crypto gainers and losers at the time of publication:
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.